Hikma Pharmaceuticals PLC (HIK.L) Stock
Hikma Pharmaceuticals PLC

Company profile
Hikma Pharmaceuticals reported revenue of $3.35 billion for fiscal year 2025, up 7.1% from fiscal year 2024, and net income of $402.00 million. That is a net profit margin of 12.0% for fiscal year 2025. Its largest business segment, Injectables, brought in 42% of segment revenue in fiscal year 2025; United States was the largest region with 58%. Our analysis of its filings shows revenue growing from $2.88 billion in fiscal year 2023 to $3.35 billion in fiscal year 2025, 7.9% a year on average. Hikma Pharmaceuticals reports about 9,500 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Largest shareholders
- Darhold Ltd.28.74%
- JPMorgan (Suisse) SA6.71%
- Wellington Management Co. LLP3.82%
- BlackRock Advisors (UK) Ltd.2.53%
- Capital Bank Of Jordan2.29%
Share of the company, as of September 25, 2026
Leadership
- H.E Said Darwazah — Chief Executive Officer, 68
- Mazen Samih Taleb Darwazeh — Executive Vice Chairman & Deputy CEO of MENA, 67
- Khalid Walid Hussni Al Nabilsi CPA — Deputy CEO of North America and Europe & Director, 53
- Areb AL KURDI — VP, Group Financial Controller & Acting CFO, 51
- Patricia Bousfield — Chief Information Officer
How much revenue does Hikma Pharmaceuticals make?
Hikma Pharmaceuticals reported $3.35 billion in revenue for fiscal year 2025, up 7.1% from $3.13 billion in fiscal year 2024.
What is Hikma Pharmaceuticals's largest business segment?
Injectables, with $1.42 billion or 42% of segment revenue in fiscal year 2025. Next: Hikma Rx (31%) and Branded (25%).
Where does Hikma Pharmaceuticals make most of its revenue?
United States: 58% of revenue by region in fiscal year 2025, followed by Other Middle East and North Africa (16%).
What companies are similar to Hikma Pharmaceuticals?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (0QFP.IL), UCB SA (0NZT.IL), Grifols, S.a. (0RDV.IL), International Biotechnology Ord (IBT.L).
How has Hikma Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $2.55 billion; FY2022, $2.52 billion; FY2023, $2.88 billion; FY2024, $3.13 billion; FY2025, $3.35 billion.
Company Information
Data as of .
How to cite: DataPorium, “Hikma Pharmaceuticals PLC (HIK.L)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/HIK.L